Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 69

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 69
---
. Each of these statements
is qualified in all respects by this reference. The SEC maintains a website that contains reports, proxy statements, and other information
about registrants, like us, that file electronically with the SEC. The address of that website is . The information
contained in, or that can be accessed through, the SEC’s website is not incorporated by reference in, and is not part of, this prospectus
or any prospectus supplement.

We are subject to the information
and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the
SEC. We maintain a website at https://www.armatapharma.com/. You may access our annual reports on Form 10-K, quarterly reports on
Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or
15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically
filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by
reference in, and is not part of, this prospectus.

<div align='center'>30

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to “incorporate
by reference” information that we file with it, which means that we can disclose important information to you by referring you to
those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes
information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while information that we file
later with the SEC will automatically update and supersede the information in this prospectus to the extent that a statement contained
in this prospectus or free writing prospectus provided to you in connection with this offering, or in any other document we subsequently
file with the SEC that also is incorporated by reference in this prospectus, modifies or supersedes the original statement.

The following documents, which
we have filed with the SEC are incorporated by reference in this prospectus:

All documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act after the date of this prospectus and prior to the
termination of all offerings covered by this prospectus hereby shall be deemed